RPA1 and neoplasm: A more recent exome-wide association study of 31,870 common SNPs involving 5553 patients with NPC has also identified a novel germline polymorphism in RPA1 (rs1131636) conferring tumor progression and therapeutic resistance in NPC, which ultimately affects the patient’s survival [16].